Amgen stock (US0311621009): Q1 2026 earnings beat estimates with revenue up 5.8%

Amgen, a leading biotechnology firm, released its Q1 2026 earnings on April 30, 2026, showing revenue of $8.62 billion, up 5.8% year-over-year and above the consensus estimate of $8.58 billion, according to MarketBeat as of May 12, 2026. Adjusted EPS came in at $5.15, beating expectations of $4.77 by $0.38. The results highlight resilient demand for its portfolio of therapies targeting inflammation, oncology, and rare diseases.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Amgen Inc.: core business model

Amgen Inc. develops and markets human therapeutics based on cellular and molecular biology, focusing on high unmet medical needs. Its portfolio includes blockbuster drugs like Enbrel for rheumatoid arthritis, Prolia for osteoporosis, and Repatha for cholesterol reduction. The company invests heavily in R&D, with a pipeline emphasizing biologics and biosimilars, according to its investor relations site.

Listed on Nasdaq under ticker AMGN, Amgen generates the majority of its revenue from the US market, making it a key player for American investors tracking biotech exposure to healthcare spending trends.

Main revenue and product drivers for Amgen Inc.

Enbrel and Otezla drive inflammation revenue, while oncology products like Kyprolis and Xgeva contribute significantly. In Q4 CY2025, total revenue reached $9.87 billion, up 8.6% year-over-year, per StockStory as of May 2026. Q1 2026 continued this momentum with $8.62 billion in sales.

Amgen's full-year 2026 EPS guidance of $21.70-$23.10 reflects confidence in product growth and pipeline advancements, positioning it well in the competitive biotech landscape.

Industry trends and competitive position

The biotech sector faces patent cliffs but benefits from innovation in gene therapy and immunology. Amgen's 27.6% operating margin in Q4 CY2025, up from 25.4% prior year, underscores operational efficiency amid pricing pressures in the US market.

Why Amgen Inc. matters for US investors

As a Nasdaq-listed biotech giant with substantial US revenue exposure, Amgen offers retail investors access to advancements in treatments for chronic diseases prevalent in the American population. Its market cap of approximately $185.6 billion as of recent reports provides scale and dividend appeal.

Conclusion

Amgen's recent Q1 2026 earnings beat, with revenue growth and positive guidance, signals ongoing strength in its core franchises. While the stock has shown stability post-earnings, investors monitor pipeline progress and competitive dynamics. The company's US-centric operations and dividend history remain attractive amid biotech volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.